JAJosé Leonidas Alves-Junior

José Leonidas Alves-Junior

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


José Leonidas Alves-Junior has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Evaluating sotatercept in the treatment of pulmonary arterial hypertension

    by William Salibe-Filho, Nathalia Zorze Rossetto, Luiza Sarmento Tatagiba, Yuri de Deus MontAlverne Parente, Carlos Viana Poyares Jardim, Caio Julio Cesar Fernandes, José Leonidas Alves-Junior, Rogerio Souza

    Pulmonary arterial hypertension (PAH) is a progressive disease characterized by pulmonary vascular remodeling, right ventricular overload, and premature death. Despite advances achieved through endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, and prostacyclin analogs, these agents primarily act as vasodilators and do not reverse underlying vascular pathology. Sotatercept, a first-in-class activin signaling modulator, restores the balance between pro- and antiproliferative signaling within the pulmonary vasculature via the TGF-β/activin-BMPR2 pathway, offering a novel disease-modifying mechanism. Following encouraging preclinical data, a series of clinical trials, PULSAR, SPECTRA, STELLAR, ZENITH, and HYPERION, demonstrated consistent efficacy across diverse PAH populations. Sotatercept significantly reduced pulmonary vascular resistance, improved exercise capacity, and decreased morbidity and mortality, including in patients receiving maximal background therapy. Across studies, adverse events were generally mild to moderate, with epistaxis, telangiectasia, and increased hemoglobin being the most common treatment-related events. Collectively, these findings establish sotatercept as a major advance in PAH therapy, marking a transition from purely vasodilatory approaches toward targeted modulation of vascular remodeling. By improving pulmonary hemodynamics and right ventricular function, sotatercept represents a new therapeutic option for improving clinical outcomes across different stages of PAH.


  • The Pacemaker Cable as an Unexpected Cause of Recurrent Pulmonary Embolism

    by William Salibe-Filho, José Leonidas Alves-Junior, Tan Chen Wu, Gabriel Navarrete, Wagner Tadeu Jurevicius Do Nascimento, Rogério Souza

  • Open Access

    Diagnosis of pulmonary arterial hypertension: a statement from the Brazilian Thoracic Association

    by Jose Leonidas Alves-Jr1, Veronica Moreira Amado2, Ricardo Amorim Correa3, Frederico A F Thadeu Campos4, Caio Fernandes1, Eloara V M Ferreira5, Marcelo B Gazzana6, Marcelo Jorge Jacó Rocha7, Carlos Jardim1, Jaquelina S Ota-Arakaki5, et al.

    Pulmonary arterial hypertension (PAH) is a condition that predominantly affects the pulmonary arterial bed, leading to pulmonary vascular remodeling, progressive decrease in pulmonary arterial compliance, and increase in pulmonary vascular resistance. The symptoms of PAH are nonspecific, which often contributes to diagnostic challenges and significant delays in establishing the diagnosis. The investigation of PAH is extensive and involves thorough search for potential clinical conditions that may contribute to its development, as well as the exclusion of other causes of pulmonary hypertension. The proper hemodynamic definition of PAH requires right heart catheterization (RHC) and direct measurements of mean pulmonary artery pressure, pulmonary arterial wedge pressure, cardiac output, and pulmonary vascular resistance. Additionally, RHC allows the assessment of the severity of the disease and, in selected cases, the identification of patients with a positive pulmonary vascular vasoreactivity test. RHC also provides valuable longitudinal information for risk stratification and patient follow-up. In the current manuscript, we review the PAH diagnostic workup, including a detailed review of the most up-to-date recommendations for right RHC and patient risk stratification.


  • Open Access

    Upfront combination therapy with sildenafil and ambrisentan in patients with chronic thromboembolic pulmonary hypertension

    by William Salibe-Filho1, Tulio Martins Vieira1, José Leonidas Alves-Junior1, Yally Priscila Pessôa Nascimento1, Luiza Sarmento Tatagiba1, Caio Julio Cesar Fernandes1, Carlos Viana Poyares Jardim1, Mario Terra-Filho1, Rogerio Souza1

    Objective: Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of acute pulmonary embolism, being characterized by persistent obstruction of pulmonary vessels and leading to increased pulmonary vascular resistance and right ventricular failure. Although pulmonary endarterectomy is the preferred treatment, medical therapies may offer clinical benefits in specific settings. We sought to evaluate the clinical and hemodynamic response of CTEPH patients treated with sildenafil and ambrisentan upfront combination therapy. Methods: This was a retrospective cohort study including patients with operable and inoperable CTEPH. The patients were followed from 2019 to 2022 and were treated with sildenafil and ambrisentan as first-line therapy. Results: Functional and hemodynamic data were analyzed at baseline and after a minimum of six months of therapy. Following treatment, there was a notable improvement in functional class, natriuretic peptide levels, and invasive hemodynamics. Conclusions: The combined use of sildenafil and ambrisentan appears to be associated with clinical, functional, and hemodynamic improvement in patients with CTEPH.


  • Open Access

    Mechanisms of exercise limitation and prevalence of pulmonary hypertension in hypersensitivity pneumonitis

    by Guilherme das Posses Bridi, Bianca Freire da Silva, Juliana Barbosa Sobral-Alves, Celso R. F. Carvalho, Joao Marcos Salge, Jose Leonidas Alves-Jr, Carlos Roberto Ribeiro de Carvalho, Ronaldo Adib Kairalla, Rogerio Souza, Bruno Guedes Baldi

    Background: Hypersensitivity pneumonitis (HP) is an immune-mediated condition triggered by inhaled antigens in susceptible individuals. Patients with HP often present with exercise limitation due to multiple mechanisms, including ventilatory and cardiocirculatory impairments, particularly pulmonary hypertension (PH). Methods: In this cross-sectional study, patients with HP of varying severity underwent clinical assessment, including quality-of-life questionnaires, incremental treadmill cardiopulmonary exercise testing (CPET), pulmonary function testing, 6-min walk test and transthoracic echocardiography (TTE). Patients with a diffusing capacity of the lung for carbon monoxide ( D LCO ) below 40% of predicted and/or a tricuspid regurgitation velocity >2.5 m·s −1 or pulmonary artery systolic pressure >35 mmHg on TTE were referred for right heart catheterisation. Results: Among 90 patients, 65% were female, with a median age of 65.5 years, and 85% had fibrotic HP. CPET was performed in 51 patients (56%), with a mean peak oxygen consumption of 58±13% of predicted. Exercise capacity was reduced in 98% of patients, with multifactorial limitation in 88%, primarily due to cardiocirculatory impairment (76%) and impaired gas exchange (66%). The mean 6-min walk distance was 334±116 m. Mean forced vital capacity and D LCO were 56±20% and 42±22% predicted, respectively. PH was identified in 59% of patients (95% CI 48–72%), predominantly with combined post- and pre-capillary involvement. Conclusions: Reduced exercise capacity is highly prevalent in patients with HP and is typically multifactorial. PH is also common, with a predominance of combined post- and pre-capillary patterns. These findings underscore the need for a comprehensive evaluation strategy in symptomatic HP patients.


  • Open Access

    Riociguat for CTEPH: A retrospective cohort study from a single reference center in Brazil

    by Caio Julio Cesar dos Santos Fernandes, William Salibe-Filho, José Leônidas Alves-Jr, Carlos Vianna Poyares Jardim, Túlio Martins Vieira, Mario Terra-Filho, Rogerio de Souza


  • Open Access

    Loss of response to calcium channel blockers after long-term follow-up treatment in patients with idiopathic pulmonary arterial hypertension

    by Bruna Piloto, Caio Julio Cesar dos Santos Fernandes, Carlos Jardim, Marcela Castro, Jose Leonidas Alves-Jr, Rogerio Souza

    Idiopathic pulmonary arterial hypertension (PAH) patients with a positive response to acute vasodilator challenge and a clinical response to calcium channel blockers (CCBs) for at least one year are traditionally designated true responders. Nevertheless, little is known about a sustained response to CCBs over longer periods of time. We evaluated the loss of response to CCBs after long-term treatment in a cohort of idiopathic PAH patients previously classified as being true responders. Our data suggest that idiopathic PAH patients can lose clinical response to CCBs even after one year of clinical stability, reinforcing the need for constant multidimensional reevaluation to assess the need for targeted PAH therapies and to classify these patients correctly.


  • Open Access

    Clinical presentation and in-hospital prognosis of lung cancer patients presenting with suspected and confirmed COVID-19

    by D. Peixoto, J.P.B. Callia, M.S. Bittencourt, G. Generoso, V.M. Anastácio, J.L. Alves-Jr., T.L. da Silva, J.C. Belizário, B.L.M. Araújo, W. Ho, et al.

    We sought to compare the clinical presentation and prognosis of patients with lung cancer and confirmed COVID-19 infection to those with negative RT-PCR SARS-CoV-2 results. We included patients with confirmed lung cancer and suspected COVID-19 who presented to the emergency department. The primary outcome was in-hospital mortality and secondary outcomes included admission to intensive care unit (ICU) or mechanical ventilation. We analyzed the characteristics according to RT-PCR results and primary outcome. We constructed a logistic regression for each RT-PCR result group to find potential predictors of the primary outcome. Among 110 individuals with confirmed lung cancer (65±9 years, 51% male), 38 patients had positive RT-PCR and 72 patients had negative RT-PCR. There was no difference between groups for any clinical characteristic or comorbidities though individuals with confirmed COVID-19 had higher functionality in the ECOG scale. Leucocytes and lymphocytes were lower in individuals with positive tests. The primary outcome occurred in 58 (53%) individuals, 37 (34%) were admitted to the ICU, and 29 (26%) required mechanical ventilation. Although mortality was similar between the two groups, individuals with confirmed COVID-19 were significantly more likely to be admitted to the ICU or receive mechanical ventilation. Only lower lymphocytes and higher CRP were significantly associated with higher mortality. The clinical presentation of COVID-19 in lung cancer is not sufficient to identify higher or lower probability groups among symptomatic individuals, the overall mortality is high irrespective of RT-PCR results, and lymphopenia on admission was associated with the diagnosis and prognosis for COVID-19.


  • Open Access

    Validation of the North America expert consensus statement on reporting CT findings for COVID-19 in individuals with lung cancer

    by D. Peixoto, Y.C.S. Neves, G. Generoso, B.M.C. Loureiro, J.P.B. Callia, V.M. Anastácio, J.L. Alves Jr., E.M. Oshiro, L.R. Lima, M.V.Y. Sawamura, et al.

    The aim of our study was to validate the use of the standardized Radiological Society of North America (RSNA) reporting system in individuals with known lung cancer who presented to the emergency department with suspected COVID-19. We included patients aged 18 years or older from the Cancer Institute of the State of São Paulo (ICESP) with a confirmed diagnosis of lung cancer, admitted to the emergency department and undergoing chest computed tomography (CT) for suspicion of COVID-19. Comparison between SARS-CoV2 RT-PCR across RSNA categories was performed in all patients and further stratified by diagnosis of lung cancer progression. Among 58 individuals included in the analysis (65±9 years, 43% men), 20 had positive RT-PCR. Less than a half (43%) had no new lung findings in the CT. Positive RT-PCR was present in 75% of those with typical findings according to RSNA and in only 9% when these findings were classified as atypical or negative (P25% of lung involvement and 100% when there was >50% of lung involvement. The lung involvement score was also highly predictive of prognosis in this population as was reported for non-lung cancer individuals. Collectively, our results demonstrated that diagnostic and prognostic values of chest CT findings in COVID-19 are robust to the presence of lung abnormalities related to lung cancer.


  • Open Access

    Brazilian Thoracic Society recommendations for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension

    by Caio Julio Cesar dos Santos Fernandes, Jaquelina Sonoe Ota-Arakaki, Frederico Thadeu Assis Figueiredo Campos, Ricardo de Amorim Correa, Marcelo Basso Gazzana, Carlos Vianna Poyares Jardim, Fábio Biscegli Jatene, Jose Leonidas Alves Junior, Roberta Pulcheri Ramos, Daniela Tannus, et al.

    Chronic thromboembolic pulmonary hypertension (CTEPH) is a serious and debilitating disease caused by occlusion of the pulmonary arterial bed by hematic emboli and by the resulting fibrous material. Such occlusion increases vascular resistance and, consequently, the pressure in the region of the pulmonary artery, which is the definition of pulmonary hypertension. The increased load imposed on the right ventricle leads to its progressive dysfunction and, finally, to death. However, CTEPH has a highly significant feature that distinguishes it from other forms of pulmonary hypertension: the fact that it can be cured through treatment with pulmonary thromboendarterectomy. Therefore, the primary objective of the management of CTEPH should be the assessment of patient fitness for surgery at a referral center, given that not all patients are good candidates. For the patients who are not good candidates for pulmonary thromboendarterectomy, the viable therapeutic alternatives include pulmonary artery angioplasty and pharmacological treatment. In these recommendations, the pathophysiological bases for the onset of CTEPH, such as acute pulmonary embolism and the clinical condition of the patient, will be discussed, as will the diagnostic algorithm to be followed and the therapeutic alternatives currently available.